Company intelligence / Profile preview

Galmed Medical Reserch

Tel Aviv, Israel

Ownership: Private
Development stage: Other

Overview

Galmed Pharmaceuticals is primarily focused on developing Aramchol, a first-in-class, oral therapy targeting SCD1 for NASH and other metabolic conditions. The company has shown excellent safety profiles with metabolic and anti-fibrotic effects in clinical trials.

Therapeutic areas: OncologyCardiovascularGastroenterology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Galmed Medical Reserch.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galmed Medical Reserch.

Explore the full profile